ArticleBlood cancer journal2025

Establishing measurable residual disease trajectories for patients on treatment for newly diagnosed multiple myeloma as benchmark for deployment of T-cell redirection therapy.

Susan Bal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.